Boehringer Ingelheim, Amgen deal

Boehringer granted Amgen worldwide rights to develop and commercialize BI 836909 ( AMG 420), a compound in Phase I testing to treat relapsed and/or refractory multiple myeloma (MM). BI 836909 is a bi...